APP and Alzheimer disease: Thromboxane A2 (TXA2), a metabolic product of COX-2, has also been suggested to exacerbate Alzheimer's disease (AD) neuropathology by inducing expression of the APP and beta-amyloid (Aβ) secretion (Biringer, 2019).